MAMahnoor Ali

Mahnoor Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Mahnoor Ali has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Janus Kinase inhibitors in refractory Takayasu arteritis: a systematic review and proportion meta-analysis of efficacy and safety

    by Rija Fatima, Saira Iqbal, Fahad Amin, Khubaib Tariq Mansoor, Zohaib Hassan, Rohama Rehman, Ayesha Aman, Mamoona Muneer, Taimur Khan Gandapur, Javaria Ahmad, et al.

    Objectives: Takayasu arteritis (TAK) is a rare chronic granulomatous vasculitis affecting large arteries, causing recurrent disease despite standard treatment. This systematic review and meta-analysis aimed to evaluate efficacy and safety of Janus kinase inhibitors in patients with refractory Takayasu arteritis. Methods: We searched five major databases from inception through July 16, 2026, for observational cohorts, non-randomized interventional studies, and case series including ≥5 patients. Eligible studies enrolled adults with refractory TAK treated with JAK inhibitors. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane ROBINS-I and Joanna Briggs Institute tools. The protocol was registered in PROSPERO (CRD420261469541). GRADE was used to assess certainty of primary efficacy outcomes. Results: Eleven studies comprising 185 patients were included. The pooled clinical remission rate was 64% (95% CI, 55%–72%; I²=0%), while complete and partial remission rates were 65% (95% CI, 55%–74%) and 8% (95% CI, 4%–17%), respectively. Pooled rates of no response and relapse were 24% and 14%, respectively. Imaging improvement or stabilization was observed in 44% of patients, while glucocorticoid-sparing effects occurred in 56%. Adverse events occurred in 10% of patients, and 7% discontinued treatment because of adverse events. GRADE certainty was very low for all assessed outcomes. Conclusion: JAK inhibitors demonstrate promising clinical efficacy and a potentially manageable safety profile in refractory TAK. However, the available evidence is predominantly observational and therefore subject to confounding and other sources of bias. High-quality prospective and randomized studies are needed to establish their efficacy, comparative effectiveness, and long-term safety.